Pure Global AI
NMPB Document

NMPB factory-listing regulations, 2017

لائحة إدراج مصانع الأدوية والمستحضرات الصيدلانية والمستلزمات الطبية ومستحضرات التجميل لسنة ٢٠١٧م
Sudanالمجلس القومي للأدوية والسمومGMP/QMSEffective 2017-12-05
Document identity

لائحة إدراج مصانع الأدوية والمستحضرات الصيدلانية والمستلزمات الطبية ومستحضرات التجميل لسنة ٢٠١٧م is published by المجلس القومي للأدوية والسموم. This document is identified by its title; no separate official document code is recorded.

Instrument
Document
Full name
NMPB factory-listing regulations, 2017
Category
GMP/QMS
Source links
Source publication
Arabic
Linked source text; confirm the publisher, publication details and any later amendment or consolidated version.
Readable HTML
1 language version
Direct citations can link to a specific article or section by appending its fragment identifier.
Dates
Published
—
Effective
2017-12-05
Readable full text

Open a language version

Each version has stable passage anchors for direct citations and highlighting. The readable text is generated from an authority source and does not replace the legally controlling publication.

About this regulation

لائحة إدراج مصانع الأدوية والمستحضرات الصيدلانية والمستلزمات الطبية ومستحضرات التجميل لسنة ٢٠١٧م

Complete four-page signed Arabic factory-listing regulation, issued under section 40 of the Medicines and Poisons Act 2009. Signed 5 December 2017 and effective on signature. Article 2 repeals the 2010 foreign-factory listing regulation while preserving actions until repealed or varied. Article 4(7) requires written notification of a major change to a listed production line; article 5(5) permits delisting for an unnotified major change. Article 6 permits an additional inspection for a new production line or major line change, five years since the previous inspection, or justified exceptional inspection. The entire original has been visually transcribed and all four page images are retained. It governs factory listing and does not itself supply a complete individual-device variation procedure. Current amendments, fee instruments, listing forms and implementation rules remain under review.

This document is identified by its title; no separate official document code is recorded. Always confirm the current consolidated text and transition provisions with the official source before filing.